原发性硬化性胆管炎相关储袋炎:一种独特的临床表型
本研究比较了原发性硬化性胆管炎(PSC)患者与匹配的非PSC溃疡性结肠炎(UC)患者在回肠储袋肛管吻合术(IPAA)后发生储袋炎的临床特征和治疗结局。PSC相关储袋炎更易表现为慢性储袋炎、中重度储袋炎症和储袋前回肠炎,且对常规抗菌治疗反应更差。
要点
- PSC患者IPAA后储袋炎更易慢性化且炎症程度更重。
- PSC相关储袋炎中储袋前回肠炎更常见。
- PSC相关储袋炎对抗菌治疗反应更差,生物制剂反应无差异。
核心结论
- PSC相关储袋炎具有独特临床表型,表现为慢性储袋炎、中重度储袋炎症和储袋前回肠炎风险增加,且对常规抗菌治疗反应更差。
研究设计与样本
- 研究纳入所有接受IPAA并诊断为储袋炎的PSC患者(PSC-储袋炎,n=182),并匹配非PSC因UC行IPAA后发生储袋炎的患者(UC-储袋炎)作为对照,比较人口学、临床、内镜、组织学和治疗数据。
主要发现
- PSC-储袋炎组因难治性疾病和异型增生行IPAA的比例分别为53.9%和46.1%,UC-储袋炎组分别为88.7%和11.3%(P < .001)。
- PSC-储袋炎组慢性储袋炎发生率为68.1%,UC-储袋炎组为34.1%(P < .001)。
- PSC-储袋炎组中重度储袋炎症发生率为54.9%,UC-储袋炎组为32.4%(P < .001)。
- PSC-储袋炎组储袋前回肠炎发生率为34.1%,UC-储袋炎组为11.5%(P < .001)。
- PSC-储袋炎组慢性抗生素依赖性和抗生素难治性储袋炎发生率分别为50.6%和17.6%,UC-储袋炎组分别为25.8%和7.7%。
关键数值与推荐
- PSC-储袋炎组因难治性疾病和异型增生行IPAA的比例分别为53.9%和46.1%,UC-储袋炎组分别为88.7%和11.3%(P < .001)。
- PSC-储袋炎组慢性储袋炎发生率为68.1%,UC-储袋炎组为34.1%(P < .001)。
- PSC-储袋炎组中重度储袋炎症发生率为54.9%,UC-储袋炎组为32.4%(P < .001)。
- PSC-储袋炎组储袋前回肠炎发生率为34.1%,UC-储袋炎组为11.5%(P < .001)。
- PSC-储袋炎组慢性抗生素依赖性和抗生素难治性储袋炎发生率分别为50.6%和17.6%,UC-储袋炎组分别为25.8%和7.7%。
临床怎么用
- 对PSC患者行IPAA后应警惕慢性储袋炎、中重度炎症及储袋前回肠炎的发生。
- PSC相关储袋炎对常规抗菌治疗反应可能不佳,需早期识别并考虑优化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with primary sclerosing cholangitis (PSC) commonly undergo ileal pouch-anal anastomosis (IPAA) for medically-refractory ulcerative colitis (UC) or colorectal dysplasia. Pouchitis develops more frequently in patients with PSC, potentially leading to increased morbidity. We aimed to assess clinical characteristics and treatment outcomes for pouchitis in patients with PSC compared to a matched, non-PSC cohort. METHODS: All patients with PSC who underwent IPAA and were diagnosed with pouchitis (PSC-pouchitis) were identified. A matched cohort composed of non-PSC patients who underwent IPAA for UC and subsequently developed pouchitis (UC-pouchitis) was developed. Relevant demographic, clinical, endoscopic, histologic, and treatment data were collected and compared between groups. RESULTS: Of those with PSC-pouchitis (n=182), 53.9% and 46.1% underwent IPAA for medically-refractory disease and dysplasia, respectively, compared to 88.7% and 11.3% in the UC-pouchitis group (P < .001). Patients with PSC-pouchitis were more likely to develop chronic pouchitis (68.1% vs 34.1%; P < .001), have moderate-to-severe pouch inflammation (54.9% vs 32.4%; P < .001), and prepouch ileitis (34.1% vs 11.5%; P < .001) compared to UC-pouchitis. Of those with PSC-pouchitis, 50.6% and 17.6% developed chronic antibiotic-dependent or antibiotic-refractory pouchitis, respectively, compared to 25.8% and 7.7% with UC-pouchitis. There was no difference in treatment response between the two groups with use of thiopurines, anti-tumor necrosis factor agents, and newer biologics. CONCLUSIONS: PSC-associated pouchitis presents with a unique clinical phenotype, characterized by increased risk of chronic pouchitis, moderate-to-severe pouch inflammation, prepouch ileitis, and less response to conventional antimicrobial therapy.
引用
- Quinn KP, Urquhart SA, Janssens LP, et al. Primary Sclerosing Cholangitis-Associated Pouchitis: A Distinct Clinical Phenotype. Clin Gastroenterol Hepatol. 2021. PMID: 33549866. doi:10.1016/j.cgh.2021.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。